Citations (203)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (23)
Eleni A Karavia, Evangelia Zvintzou, Peristera-Ioanna Petropoulou, Eva Xepapadaki, Caterina Constantinou & Kyriakos E Kypreos. (2014) HDL quality and functionality: what can proteins and genes predict?. Expert Review of Cardiovascular Therapy 12:4, pages 521-532.
Read now
Read now
TS Mohamed Saleem, PV Sandhya Rani & K Gauthaman. (2011) High-density lipoproteins: a novel therapeutic target for cardiovascular disease. Research Reports in Clinical Cardiology 2, pages 1-6.
Read now
Read now
Ibrahim Al-Zakwani, Kadhim Sulaiman, Khalid Al-Rasadi & Dimitri P. Mikhailidis. (2011) Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. Current Medical Research and Opinion 27:4, pages 879-885.
Read now
Read now
Jianhui Wu, Ming Zhao & Shiqi Peng. (2011) Quinazolin-4(3H)-ones capable of upregulating the expression of endogenous apolipoprotein A-1. Expert Opinion on Therapeutic Patents 21:3, pages 431-435.
Read now
Read now
Vibhuti Singh, Rakesh Sharma, Ajoy Kumar & Prakash Deedwania. (2010) Low high-density lipoprotein cholesterol: current status and future strategies for management. Vascular Health and Risk Management 6, pages 979-996.
Read now
Read now
Suman Bhandary, Ruma Basu, Sukhen Das & Papiya Nandy. (2010) Comparison of the effect of anti-hyperlipidemic drugs from different groups on the phase profile of liposomal membrane–a fluorescence anisotropy study. Phase Transitions 83:7, pages 518-525.
Read now
Read now
Rakesh K Sharma, Vibhuti N Singh & Hanumanth K Reddy. (2009) Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Vascular Health and Risk Management 5, pages 793-799.
Read now
Read now
ES Nakou, TD Filippatos, DN Kiortsis, CS Derdemezis, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opinion on Pharmacotherapy 9:18, pages 3151-3158.
Read now
Read now
José V. Lozano, Vicente Pallarés, Luis Cea-Calvo, José L. Llisterri, Cristina Fernández-Pérez, Juan C. Martí-Canales, Jose Aznar, Vicente Gil-Guillén & Josep Redón. (2008) Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Current Medical Research and Opinion 24:3, pages 659-670.
Read now
Read now
Vasilios G Athyros, Konstantinos Tziomalos, Dimitri P Mikhailidis, Efstathios D Pagourelias, Anna I Kakafika, Athanasios Skaperdas, Apostolos Hatzitolios & Asterios Karagiannis. (2007) Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opinion on Pharmacotherapy 8:14, pages 2267-2277.
Read now
Read now
J Rumi Jaumdally, Chetan Varma & Gregory YH Lip. (2007) Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?. Expert Opinion on Pharmacotherapy 8:9, pages 1235-1243.
Read now
Read now
Mihalis Kalogirou, Vasilis Tsimihodimos, Irene Gazi, Theodosios Filippatos, Vasilis Saougos, Alexandros D. Tselepis, Dimitri P. Mikhailidis & Moses Elisaf. (2007) Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Current Medical Research and Opinion 23:5, pages 1169-1176.
Read now
Read now
Anthony S. Wierzbicki, Emmanuel S. Ganotakis & Dimitri P. Mikhailidis. (2007) Shape of the Nations survey and attitudes to cardiometabolic risk. Current Medical Research and Opinion 23:1, pages 25-28.
Read now
Read now
Irene F Gazi & Dimitri P Mikhailidis. (2006) Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opinion on Therapeutic Targets 10:6, pages 851-866.
Read now
Read now
Anthony Wierzbicki. (2006) Future approaches to reducing low-density lipoprotein cholesterol. Future Lipidology 1:4, pages 463-476.
Read now
Read now
Boris Hansel, Anatol Kontush, Philippe Giral, Dominique Bonnefont-Rousselot, M. John Chapman & Eric Bruckert. (2006) One third of the variability in HDL‐cholesterol level in a large dyslipidaemic population is predicted by age, sex and triglyceridaemia:The Paris La Pitié Study. Current Medical Research and Opinion 22:6, pages 1149-1160.
Read now
Read now
Stella S. Daskalopoulou & Dimitri P. Mikhailidis. (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current Medical Research and Opinion 22:3, pages 511-528.
Read now
Read now
Shah Shah. (2006) HDL/apoA-I infusion for atherosclerosis management: an emerging therapeutic paradigm. Future Lipidology 1:1, pages 55-64.
Read now
Read now
Eric Bruckert, Marie Baccara-Dinet, Fran McCoy & John Chapman. (2005) High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Current Medical Research and Opinion 21:12, pages 1927-1934.
Read now
Read now
Grant H Skrepnek. (2005) Cost–effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. Expert Review of Pharmacoeconomics & Outcomes Research 5:5, pages 603-623.
Read now
Read now
Prakash Deedwania & Natalia Volkova. (2005) Dyslipidemia and lipid-lowering therapy in the elderly. Expert Review of Cardiovascular Therapy 3:3, pages 453-463.
Read now
Read now
Mark E. McGovern. (2005) Taking aim at HDL-C. Postgraduate Medicine 117:4, pages 29-44.
Read now
Read now
Anthony S Wierzbicki. (2004) Lipid-lowering therapies in development. Expert Opinion on Investigational Drugs 13:11, pages 1405-1418.
Read now
Read now
Articles from other publishers (180)
Camille Gautier & Christine Aurich. (2022) “Fine feathers make fine birds” – The mammalian sperm plasma membrane lipid composition and effects on assisted reproduction. Animal Reproduction Science 246, pages 106884.
Crossref
Crossref
María Luna-Luna, Eric Niesor & Óscar Pérez-Méndez. (2022) HDL as Bidirectional Lipid Vectors: Time for New Paradigms. Biomedicines 10:5, pages 1180.
Crossref
Crossref
Cesare R. Sirtori, Alberto Corsini & Massimiliano Ruscica. (2022) The Role of High-Density Lipoprotein Cholesterol in 2022. Current Atherosclerosis Reports 24:5, pages 365-377.
Crossref
Crossref
Maricela Aceves-Ramírez, Yeminia Valle, Fidel Casillas-Muñoz, Diana Emilia Martínez-Fernández, Brenda Parra-Reyna, Víctor Arturo López-Moreno, Héctor Enrique Flores-Salinas, Emmanuel Valdés-Alvarado, José Francisco Muñoz-Valle, Texali García-Garduño & Jorge Ramón Padilla-Gutiérrez. (2022) Analysis of the APOB Gene and Apolipoprotein B Serum Levels in a Mexican Population with Acute Coronary Syndrome: Association with the Single Nucleotide Variants rs1469513, rs673548, rs676210, and rs1042034. Genetics Research 2022, pages 1-8.
Crossref
Crossref
Zhitong Zheng, Jieli Chen & Michael Chopp. 2022. Stroke. Stroke
129
137.e7
.
Serkan Mutlu, Adem Parlak, Umit Aydogan, Aydogan Aydogdu, Bugra Soykut, Cemal Akay, Kenan Saglam & Abdullah Taslipinar. (2013) The effect of levothyroxine replacement therapy on lipid profile and oxidative stress parameters in patients with subclinical hypothyroid. Archives of Pharmacal Research 44:8, pages 1-9.
Crossref
Crossref
Subrina JesminFarzana SohaelMd. Arifur RahmanAdil MaqboolMd. Majedul IslamTakeru Shima, Nobutake ShimojoMasao Moroi, Naoto Yamaguchi, Koichi Watanabe, Fumi Takeda & Hideaki Soya. (2020) Short-term lifestyle intervention program through daily walking improves circulatory low HDL level in rural Bangladeshi women. The Journal of Physical Fitness and Sports Medicine 9:4, pages 181-190.
Crossref
Crossref
Tarek K. Motawi, Nermin A. H. Sadik, Manal A. Hamed, Sanaa A. Ali, Wagdy K. B. Khalil & Yomna R. Ahmed. (2019) Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson’s disease mice model. Molecular and Cellular Biochemistry 465:1-2, pages 89-102.
Crossref
Crossref
Otto Henrique Nienov, Fernanda Dapper Machado, Lisiane Stefani Dias, Luiz Alberto De Carli & Helena Schmid. (2019) Effect of Bariatric Surgery on High-Density Lipoprotein (HDL) Cholesterol in Non-diabetic Patients with Severe Obesity. Obesity Surgery 30:1, pages 154-160.
Crossref
Crossref
Kuen-Ming Wu, Yuan-Man Hsu, Mei-Chin Ying, Fuu-Jen Tsai, Chang-Hai Tsai, Jing-Gung Chung, Jai-Sing Yang, Chih-Hsin Tang, Li-Yi Cheng, Po-Hua Su, Vijaya Padma Viswanadha, Wei-Wen Kuo & Chih-Yang Huang. (2019) High-density lipoprotein ameliorates palmitic acid-induced lipotoxicity and oxidative dysfunction in H9c2 cardiomyoblast cells via ROS suppression. Nutrition & Metabolism 16:1.
Crossref
Crossref
Sang‐Hee Lee, Yu‐Jin Kim, Byeong Ho Kang & Choon‐Keun Park. (2019) Effect of nicotinic acid on the plasma membrane function and polyunsaturated fatty acids composition during cryopreservation in boar sperm. Reproduction in Domestic Animals 54:9, pages 1251-1257.
Crossref
Crossref
Kyriakos E. Kypreos, Rafael Bitzur, Eleni A. Karavia, Eva Xepapadaki, George Panayiotakopoulos & Caterina Constantinou. (2018) Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. Angiology 70:3, pages 197-209.
Crossref
Crossref
Martin B Whyte. (2019) Is high-density lipoprotein a modifiable treatment target or just a biomarker for cardiovascular disease?. JRSM Cardiovascular Disease 8, pages 204800401986973.
Crossref
Crossref
Baolei Fan, Jinmao You, Yourui Suo & Chunqi Qian. (2018) A novel and sensitive method for determining vitamin B3 and B7 by pre-column derivatization and high-performance liquid chromatography method with fluorescence detection. PLOS ONE 13:6, pages e0198102.
Crossref
Crossref
Su-Ying Wen, Bharath Kumar Velmurugan, Cecilia Hsuan Day, Chia-Yao Shen, Li-Chin Chun, Yi-Chieh Tsai, Yueh-Min Lin, Ray-Jade Chen, Chia-Hua Kuo & Chih-Yang Huang. (2017) High density lipoprotein (HDL) reverses palmitic acid induced energy metabolism imbalance by switching CD36 and GLUT4 signaling pathways in cardiomyocyte. Journal of Cellular Physiology 232:11, pages 3020-3029.
Crossref
Crossref
Rgia A. Othman, Semone B. Myrie, David Mymin, Jean-Baptiste Roullet, Robert D. Steiner & Peter J.H. Jones. (2017) Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia. Atherosclerosis 260, pages 27-33.
Crossref
Crossref
Yingzi Chang & Jacques Robidoux. (2017) Dyslipidemia management update. Current Opinion in Pharmacology 33, pages 47-55.
Crossref
Crossref
Tarek K. Motawi, Hebatallah A. Darwish, Manal A. Hamed, Nagy S. El-Rigal & Asmaa F. Aboul Naser. (2016) A Therapeutic Insight of Niacin and Coenzyme Q10 Against Diabetic Encephalopathy in Rats. Molecular Neurobiology 54:3, pages 1601-1611.
Crossref
Crossref
Courtney L Millar, Quinn Duclos & Christopher N Blesso. (2017) Effects of Dietary Flavonoids on Reverse Cholesterol Transport, HDL Metabolism, and HDL function. Advances in Nutrition 8:2, pages 226-239.
Crossref
Crossref
Gian Carlo TenoreDomenico CarusoGiuseppe BuonomoMaria D'AvinoPietro CampigliaLuciana MarinelliEttore Novellino. (2017) A Healthy Balance of Plasma Cholesterol by a Novel Annurca Apple-Based Nutraceutical Formulation: Results of a Randomized Trial. Journal of Medicinal Food 20:3, pages 288-300.
Crossref
Crossref
L. F. Wang, S. D. Jia, G. Q. Yang, R. Y. Liu, G. Y. Yang, M. Li, H. S. Zhu, Y. Y. Wang & L. Q. Han. (2017)
The effects of acute lipopolysaccharide challenge on dairy goat liver metabolism assessed with
1
HNMR metabonomics
. Journal of Animal Physiology and Animal Nutrition 101:1, pages 180-189.
Crossref
Crossref
Hong-Lei Xie, Chun-Chi Liu, Yi-Qun Li, Chang-Lin Bai, Chen-Zhou Hao, Jing Guo, Chang-Qun Luo, Dong-Mei Zhao & Mao-Sheng Cheng. (2017) Synthesis of novel β-propanamides to inhibit cholesteryl ester transfer protein (CETP). Chinese Chemical Letters 28:2, pages 260-263.
Crossref
Crossref
Yang Wang, Xiangda Meng & Hua Yan. (2017) Niaspan inhibits diabetic retinopathy‑induced vascular inflammation by downregulating the tumor necrosis factor‑α pathway. Molecular Medicine Reports.
Crossref
Crossref
Masoumeh Azizi, Sedigheh Hosseinpour Delavar & Abdolamir Saiiari. (2016) Comparison of Lipid and Apolipoprotein Profiles Following Two Exercise Protocols in Overweight Females. Jentashapir Journal of Health Research InPress:InPress.
Crossref
Crossref
Yang Wang & Hua Yan. (2016) MicroRNA-126 contributes to Niaspan treatment induced vascular restoration after diabetic retinopathy. Scientific Reports 6:1.
Crossref
Crossref
Dongmei Zhao, Honglei Xie, Changlin Bai, Chunchi Liu, Chenzhou Hao, Shizhen Zhao, Hongli Yuan, Changqun Luo, Jian Wang, Bin Lin, Jiang Zheng & Maosheng Cheng. (2016) Design, synthesis and biological evaluation of N,N-3-phenyl-3-benzylaminopropanamide derivatives as novel cholesteryl ester transfer protein inhibitor. Bioorganic & Medicinal Chemistry 24:8, pages 1589-1597.
Crossref
Crossref
Petra El KhouryElisa WaldmannThierry HubyJulie GallPhilippe CouvertJean-Marc LacorteJohn ChapmanEric FrisdalPhilippe LesnikKlaus G. ParhoferWilfried Le GoffMaryse Guerin. (2016) Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport. Arteriosclerosis, Thrombosis, and Vascular Biology 36:2, pages 285-294.
Crossref
Crossref
Hiroaki Satoh, Tetsuya Ohira, Masato Nagai, Mitsuaki Hosoya, Akira Sakai, Tsuyoshi Watanabe, Akira Ohtsuru, Yukihiko Kawasaki, Hitoshi Suzuki, Atsushi Takahashi, Gen Kobashi, Kotaro Ozasa, Seiji Yasumura, Shunichi Yamashita, Kenji Kamiya & Masafumi Abe. (2016) Hypo-high-density Lipoprotein Cholesterolemia Caused by Evacuation after the Fukushima Daiichi Nuclear Power Plant Accident: Results from the Fukushima Health Management Survey. Internal Medicine 55:15, pages 1967-1976.
Crossref
Crossref
Chan Seok ParkHyo-Soo KimSang-Hak LeeKi Hoon HanSang-Hyun KimDoo-Il KimMoon-Kyu LeeJi Dong SungYoung-Keun AhnJae-Hyeong ParkSang-Hong Baek. (2016) Prevalence, Treatment Pattern and Resource Use in Patients with Mixed Dyslipidemia Using Lipid Modifying Agents in Korea (PRIMULA): An Observational Study. Journal of Lipid and Atherosclerosis 5:2, pages 121.
Crossref
Crossref
Kim,Yong-Kyu, Chaesan Lee & ???. (2015) Effect of 12Weeks Combined Exercises on Inflammatory Response Indicator, Artherosclerosis Index in Obese Middle-aged Women. Official Journal of the Koeran Society of Dance Science 32:4, pages 149-162.
Crossref
Crossref
Yi Ding, YuWen Li & AiDong Wen. (2015) Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials. Clinical Nutrition 34:5, pages 838-844.
Crossref
Crossref
Jin XuYun-Fei LiaoWei-Ping ZhouHua-Li MingQing-Hai Wang. (2015)
The
MCP-1
Gene A-2518G Polymorphism Confers an Increased Risk of Vascular Complications in Type 2 Diabetes Mellitus Patients
. Genetic Testing and Molecular Biomarkers 19:8, pages 411-417.
Crossref
Crossref
Rui-Xia Xu, Sha Li, Xiao-Lin Li, Yan Zhang, Yuan-Lin Guo, Cheng-Gang Zhu, Na-Qiong Wu, Ping Qing, Jing Sun, Qian Dong & Jian-Jun Li. (2015) High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment. Journal of Clinical Lipidology 9:1, pages 26-34.
Crossref
Crossref
Bronwyn A. Kingwell, M. John Chapman, Anatol Kontush & Norman E. Miller. (2014) HDL-targeted therapies: progress, failures and future. Nature Reviews Drug Discovery 13:6, pages 445-464.
Crossref
Crossref
Marco Raffaelli, Caterina Guidone, Cosimo Callari, Amerigo Iaconelli, Rocco Bellantone & Geltrude Mingrone. (2014) Effect of Gastric Bypass Versus Diet on Cardiovascular Risk Factors. Annals of Surgery 259:4, pages 694-699.
Crossref
Crossref
Li Tian, Chuanwei Li, Yinghui Liu, Yucheng Chen & Mingde Fu. (2014) The Value and Distribution of High-Density Lipoprotein Subclass in Patients with Acute Coronary Syndrome. PLoS ONE 9:1, pages e85114.
Crossref
Crossref
Dae-Young Kim & Sun-Young Jung. (2014) Effect of Aerobic Exercise on Risk Factors of Cardiovascular Disease and the Apolipoprotein B / Apolipoprotein A-1 Ratio in Obese Woman. Journal of Physical Therapy Science 26:11, pages 1825-1829.
Crossref
Crossref
Ding Ding, Xinrui Li, Jian Qiu, Rui Li, Yuan Zhang, Dongfang Su, Zhongxia Li, Min Wang, Xiaofei Lv, Dongliang Wang, Yan Yang, Min Xia, Dan Li, Gang Hu & Wenhua Ling. (2014) Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients. BioMed Research International 2014, pages 1-11.
Crossref
Crossref
Ju-Yi Hsieh, Chiz-Tzung Chang, Max T. Huang, Chia-Ming Chang, Chia-Ying Chen, Ming-Yi Shen, Hsin-Yi Liao, Guei-Jane Wang, Chu-Huang Chen, Chao-Jung Chen & Chao-Yuh Yang. (2013) Biochemical and Functional Characterization of Charge-Defined Subfractions of High-Density Lipoprotein From Normal Adults. Analytical Chemistry 85:23, pages 11440-11448.
Crossref
Crossref
F. Rossi, C. Bertone, E. Michelon, M.J. Bianco & V. Santiemma. (2013) High-density lipoprotein cholesterol affects early endothelial progenitor cell number and endothelial function in obese women. Obesity 21:11, pages 2356-2361.
Crossref
Crossref
M.E. Ashmaig, S. Gupta, J.P. McConnell & G.R. Warnick. (2013) Validation of a novel homogeneous assay for of HDL3-C measurement. Clinica Chimica Acta 425, pages 37-41.
Crossref
Crossref
Yining Qian, Yuehua Pu, Liping Liu, David Z. Wang, Xingquan Zhao, Chunxue Wang, Yilong Wang, Gaifen Liu, Yuesong Pan & Yongjun Wang. (2013) Low HDL-C Level Is Associated with the Development of Intracranial Artery Stenosis: Analysis from the Chinese IntraCranial AtheroSclerosis (CICAS) Study. PLoS ONE 8:5, pages e64395.
Crossref
Crossref
Andrew J. Juren, Gautamn Sarwal, Ahmad Al-Sarraf, Michal Vrablik, Darren Chan, Karin H. Humphries & Jiri J. Frohlich. (2013) Low prevalence of type 2 diabetes mellitus among patients with high levels of high-density lipoprotein cholesterol. Journal of Clinical Lipidology 7:3, pages 194-198.
Crossref
Crossref
Shadi Hamoud, Tony Hayek, Ahmad Hassan, Edna Meilin, Marielle Kaplan, Rafael Torgovicky & Raanan Cohen. (2013) Niacin Administration Significantly Reduces Oxidative Stress in Patients With Hypercholesterolemia and Low Levels of High-Density Lipoprotein Cholesterol. The American Journal of the Medical Sciences 345:3, pages 195-199.
Crossref
Crossref
Xiao-Yan LIU, Qian LU, Wu-Jun CHEN & Chao-Ke TANG. (2013) New Research Advances in Genetics Associated With High-density Lipoprotein Cholesterol*. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS 39:12, pages 1145-1155.
Crossref
Crossref
U. Julius & S. Fischer. (2013) Nicotinic acid as a lipid-modifying drug – A review. Atherosclerosis Supplements 14:1, pages 7-13.
Crossref
Crossref
Adie Viljoen & Anthony S. Wierzbicki. 2012. Cardiovascular Disease and Health in the Older Patient. Cardiovascular Disease and Health in the Older Patient
68
89
.
Aneta Otocka-Kmiecik, Dimitri P. Mikhailidis, Stephen J. Nicholls, Michael Davidson, Jacek Rysz & Maciej Banach. (2012) Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. Progress in Lipid Research 51:4, pages 314-324.
Crossref
Crossref
Michael M. Miller, Yalei Liu, Ji Jiang, James A. Johnson, Muthoni Kamau, David S. Nirschl, Yufeng Wang, Lalgudi Harikrishnan, David S. Taylor, Alice Ye A. Chen, Xiaohong Yin, Ramakrishna Seethala, Tara L. Peterson, Tatyana Zvyaga, Jun Zhang, Christine S. Huang, Ruth R. Wexler, Michael A. Poss, R. Michael Lawrence, Leonard P. Adam & Mark E. Salvati. (2012) Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors. Bioorganic & Medicinal Chemistry Letters 22:20, pages 6503-6508.
Crossref
Crossref
Ruth A. Reilly & Colette Janson-Sand. (2012) Supplement Use in the Prevention and Treatment of Cardiovascular Disease in the Aging Population. American Journal of Lifestyle Medicine 6:5, pages 376-381.
Crossref
Crossref
Bing Pan, Hui Ren, Yijing Ma, Donghui Liu, Baoqi Yu, Liang Ji, Ling Pan, Jing Li, Liangui Yang, Xiaofeng Lv, Xiaoli Shen, Bin Chen, Youyi Zhang, Belinda Willard, Yubin He & Lemin Zheng. (2011) High‐density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. International Journal of Cancer 131:1, pages 70-82.
Crossref
Crossref
Ana Escribano, Ana I. Mateo, Eva M. Martin de la Nava, Daniel R. Mayhugh, Sandra L. Cockerham, Thomas P. Beyer, Robert J. Schmidt, Guoqing Cao, Youyan Zhang, Timothy M. Jones, Anthony G. Borel, Stephanie A. Sweetana, Ellen A. Cannady & Nathan B. Mantlo. (2012) Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 22:11, pages 3671-3675.
Crossref
Crossref
Maria-Carmen Fernandez, Ana Escribano, Ana I. Mateo, Saravanan Parthasarathy, Eva M. Martin de la Nava, Xiaodong Wang, Sandra L. Cockerham, Thomas P. Beyer, Robert J. Schmidt, Guoqing Cao, Youyan Zhang, Timothy M. Jones, Anthony Borel, Stephanie A. Sweetana, Ellen A. Cannady, Gregory Stephenson, Scott Frank & Nathan B. Mantlo. (2012) Design, synthesis and structure?activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 22:9, pages 3056-3062.
Crossref
Crossref
Adie Viljoen & Anthony S. Wierzbicki. 2012. Pathy's Principles and Practice of Geriatric Medicine. Pathy's Principles and Practice of Geriatric Medicine
449
460
.
Tao Yan, Michael Chopp, Xinchun Ye, Zhongwu Liu, Alex Zacharek, Yisheng Cui, Cynthia Roberts, Ben Buller & Jieli Chen. (2012) Niaspan increases axonal remodeling after stroke in type 1 diabetes rats. Neurobiology of Disease 46:1, pages 157-164.
Crossref
Crossref
Kausik K. Ray & Christopher P. Cannon. 2012. Textbook of Interventional Cardiology. Textbook of Interventional Cardiology
126
141
.
Donovan McGrowder, Cliff Riley, Errol Y. St. A. Morrison & Lorenzo Gordon. (2011) The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer. Cholesterol 2011, pages 1-9.
Crossref
Crossref
Anatol Kontush & M. John Chapman. 2011. High‐Density Lipoproteins. High‐Density Lipoproteins.
Anatol Kontush & M. John Chapman. 2011. High‐Density Lipoproteins. High‐Density Lipoproteins
113
160
.
Anatol Kontush & M. John Chapman. 2011. High‐Density Lipoproteins. High‐Density Lipoproteins
423
523
.
Xinchun Ye, Michael Chopp, Xu Cui, Alex Zacharek, Yisheng Cui, Tao Yan, Amjad Shehadah, Cynthia Roberts, Xinfeng Liu, Mei Lu & Jieli Chen. (2011) Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats. Experimental Neurology 232:2, pages 299-308.
Crossref
Crossref
Jes?s Tim?n-Zapata, Emilio Jos? Laserna-Mendieta, Daniel Pineda-Tenor, Mercedes Agudo-Macazaga, Carmen Narros-Cecilia, Mar?a Jes?s Rocha-Bogas, Guadalupe Ruiz-Mart?n & Manuel G?mez-Serranillos. (2011) Extreme concentrations of high density lipoprotein cholesterol affect the calculation of low density lipoprotein cholesterol in the Friedewald formula and other proposed formulas. Clinical Biochemistry 44:17-18, pages 1451-1456.
Crossref
Crossref
Anthony S. Wierzbicki. (2011) HDL: who needs it?. International Journal of Clinical Practice 65:11, pages 1111-1113.
Crossref
Crossref
Amjad Shehadah, Jieli Chen, Yisheng Cui, Li Zhang, Cynthia Roberts, Mei Lu & Michael Chopp. (2011) Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats. Journal of the Neurological Sciences 309:1-2, pages 96-101.
Crossref
Crossref
??? Siyoung Kim & YoungSoo Lee. (2011) Effects of exercise intensity on HDL-C subparticles and atherogenic index.. Exercise Science 20:3, pages 309-318.
Crossref
Crossref
Zhen-yu Peng, Shui-ping Zhao, Bai-mei He, Dao-quan Peng & Min Hu. (2011) Protective effect of HDL on endothelial NO production: the role of DDAH/ADMA pathway. Molecular and Cellular Biochemistry 351:1-2, pages 243-249.
Crossref
Crossref
Shao Hong, -Quan Chen Li & Xu Jun. (2011) Treatment of dyslipidemia in the elderly. Journal of Geriatric Cardiology 8:1, pages 55-64.
Crossref
Crossref
A. S. Wierzbicki. (2011) Niacin: the only vitamin that reduces cardiovascular events. International Journal of Clinical Practice 65:4, pages 379-385.
Crossref
Crossref
Dina M. Schreinemachers. (2011) Association between Perchlorate and Indirect Indicators of Thyroid Dysfunction in NHANES 2001–2002, a Cross-Sectional, Hypothesis-Generating Study. Biomarker Insights 6, pages BMI.S7985.
Crossref
Crossref
Alexandros Vakalopoulos, Carsten Schmeck, Michael Thutewohl, Volkhart Li, Hilmar Bischoff, Klemens Lustig, Olaf Weber, Holger Paulsen & Harry Elias. (2011) Chromanol derivatives—A novel class of CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 21:1, pages 488-491.
Crossref
Crossref
Peter L. Thompson & Philip Barter. 2011. Coronary Care Manual. Coronary Care Manual
328
337
.
Peter P. Toth. 2011. Comprehensive Cardiovascular Medicine in the Primary Care Setting. Comprehensive Cardiovascular Medicine in the Primary Care Setting
59
89
.
Robert S. Rosenson. 2011. Hyperlipidemia in Primary Care. Hyperlipidemia in Primary Care
159
171
.
Tasneem Z. Naqvi. 2011. Asymptomatic Atherosclerosis. Asymptomatic Atherosclerosis
285
318
.
Mohammad Ali Kashani Farid, Fereidoun Azizi, Mehdi Hedayati, Maryam S Daneshpour, Ahmad Reza Shamshiri & Fereydoun Siassi. (2010) Association between CETP Taq1B and LIPC -514C/T polymorphisms with the serum lipid levels in a group of Tehran's population: a cross sectional study. Lipids in Health and Disease 9:1.
Crossref
Crossref
Dina M Schreinemachers. (2010) Perturbation of lipids and glucose metabolism associated with previous 2,4-D exposure: a cross-sectional study of NHANES III data, 1988-1994. Environmental Health 9:1.
Crossref
Crossref
Natalie D. Muth, Gail A. Laughlin, Denise von Mühlen, Sidney C. Smith & Elizabeth Barrett-Connor. (2010) High-density lipoprotein subclasses are a potential intermediary between alcohol intake and reduced risk of cardiovascular disease: The Rancho Bernardo Study. British Journal of Nutrition 104:07, pages 1034-1042.
Crossref
Crossref
P. Tuohimaa & M. Järvilehto. (2010) Niacin in the prevention of atherosclerosis: Significance of vasodilatation. Medical Hypotheses 75:4, pages 397-400.
Crossref
Crossref
Sergio Fazio & MacRae F. Linton. (2010) High-density lipoprotein therapeutics and cardiovascular prevention. Journal of Clinical Lipidology 4:5, pages 411-419.
Crossref
Crossref
E. Bruckert, M. Farnier & J. Ferrières. (2010) HDL-cholestérol et risque cardiovasculaire : au-delà du LDL !. Médecine des Maladies Métaboliques 4:4, pages 379-388.
Crossref
Crossref
Daphna Weissglas-Volkov & Päivi Pajukanta. (2010) Genetic causes of high and low serum HDL-cholesterol. Journal of Lipid Research 51:8, pages 2032-2057.
Crossref
Crossref
Peter P. Toth. (2010) Drug Treatment of Hyperlipidaemia. Drugs 70:11, pages 1363-1379.
Crossref
Crossref
Andrew J Murphy & Kevin J Woollard. (2009) High-density lipoprotein: A potent inhibitor of inflammation. Clinical and Experimental Pharmacology and Physiology 37:7, pages 710-718.
Crossref
Crossref
M. John Chapman, Jan S. Redfern, Mark E. McGovern & Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, pages 314-345.
Crossref
Crossref
Eric Bruckert, Julien Labreuche & Pierre Amarenco. (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210:2, pages 353-361.
Crossref
Crossref
Adeseye A. Akintunde, E. Olugbenga Ayodele, Olayinka P. Akinwusi & George O. Opadijo. (2010) Dyslipidemia Among Newly Diagnosed Hypertensives: Pattern and Clinical Correlates. Journal of the National Medical Association 102:5, pages 403-407.
Crossref
Crossref
Carsten Schmeck, Heike Gielen-Haertwig, Alexandros Vakalopoulos, Hilmar Bischoff, Volkhart Li, Gabriele Wirtz & Olaf Weber. (2010) Novel tetrahydrochinoline derived CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 20:5, pages 1740-1743.
Crossref
Crossref
Anthony S. Wierzbicki & Simon R. Redwood. 2010. The Evidence Base for Diabetes Care. The Evidence Base for Diabetes Care
355
376
.
M. J. Chapman, W. Le Goff, M. Guerin & A. Kontush. (2009) Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. European Heart Journal 31:2, pages 149-164.
Crossref
Crossref
P.P. Toth. (2010) Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. Yearbook of Endocrinology 2010, pages 60-62.
Crossref
Crossref
Giovanna Catalano & Maryse Guerin. 2010. The HDL Handbook. The HDL Handbook
61
76
.
M?rcia Braz Rossetti, Raquel Rodrigues Britto & Rocksane de Carvalho Norton. (2009) Preven??o prim?ria de doen?as cardiovasculares na obesidade infantojuvenil: efeito anti-inflamat?rio do exerc?cio f?sico. Revista Brasileira de Medicina do Esporte 15:6, pages 472-475.
Crossref
Crossref
E. Windler, B.-Chr. Zyriax, Chr. Bamberger, F. Rinninger & F.-U. Beil. (2009) Current Strategies and Recent Advances in the Therapy of Hypercholesterolemia. Atherosclerosis Supplements 10:5, pages 1-4.
Crossref
Crossref
Aart C. Strang, G. Kees Hovingh, Erik S.G. Stroes & John J.P. Kastelein. (2009) The Genetics of High-Density Lipoprotein Metabolism: Clinical Relevance for Therapeutic Approaches. The American Journal of Cardiology 104:10, pages 22E-31E.
Crossref
Crossref
Prakash Deedwania, Vibhuti Singh & Michael H. Davidson. (2009) Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials. The American Journal of Cardiology 104:10, pages 3E-9E.
Crossref
Crossref
Alessandra GattiMarianna MaranghiSimonetta BacciClaudio CaralloAgostino GnassoElisabetta MandosiMara FallarinoSusanna MoranoVincenzo TrischittaSebastiano Filetti. (2009) Poor Glycemic Control Is an Independent Risk Factor for Low HDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 32:8, pages 1550-1552.
Crossref
Crossref
A.I. Hatzitolios, V.G. Athyros, A. Karagiannis, C. Savopoulos, C. Charalambous, G. Kyriakidis, Th. Milidis, C. Papathanakis, A. Bitli, I. Vogiatsis, G. Ntaios, N. Katsiki, A. Symeonidis, K. Tziomalos & D.P. Mikhailidis. (2009) Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. International Journal of Cardiology 134:3, pages 322-329.
Crossref
Crossref
Michael S. Kostapanos, Haralampos J. Milionis, Theodosios D. Filippatos, Leonidas G. Christogiannis, Eleni T. Bairaktari, Alexandros D. Tselepis & Moses S. Elisaf. (2009) Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 14:1, pages 5-13.
Crossref
Crossref
K. G. Lagos, T. D. Filippatos, V. Tsimihodimos, I. F. Gazi, C. Rizos, A. D. Tselepis, D. P. Mikhailidis & Moses S. Elisaf. (2008) Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome. Lipids 44:1, pages 9-16.
Crossref
Crossref
Christoph Wanner & Eberhard Ritz. (2008) Reducing lipids for CV protection in CKD patients—current evidence. Kidney International 74, pages S24-S28.
Crossref
Crossref
José W.A. van der HoornWilleke de HaanJimmy F.P. BerbéeLouis M. HavekesJ. Wouter JukemaPatrick C.N. RensenHans M.G. Princen. (2008)
Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in
APOE*3Leiden.CETP
Mice
. Arteriosclerosis, Thrombosis, and Vascular Biology 28:11, pages 2016-2022.
Crossref
Crossref
Karthikeyan Mythreye, Lisa L. Satterwhite, W. Sean Davidson & Pascal J. Goldschmidt-Clermont. (2008) ApoA-I induced CD31 in bone marrow-derived vascular progenitor cells increases adhesion: Implications for vascular repair. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1781:11-12, pages 703-709.
Crossref
Crossref
Peter P. Toth. (2009) When high is low: Raising low levels of high-density lipoprotein cholesterol. Current Cardiology Reports 10:6, pages 488-496.
Crossref
Crossref
T. D. Filippatos, E. N. Liberopoulos, M. Kostapanos, I. F. Gazi, E. C. Papavasiliou, D. N. Kiortsis, A. D. Tselepis & M. S. Elisaf. (2008) The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes, Obesity and Metabolism 10:6, pages 476-483.
Crossref
Crossref
Tamar S. Polonsky & Michael H. Davidson. (2008) Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy. The American Journal of Cardiology 101:8, pages S27-S35.
Crossref
Crossref
Giovanna Catalano, Emilie Duchene, Zélie Julia, Wilfried Le Goff, Eric Bruckert, M. John Chapman & Maryse Guerin. (2008) Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects. Journal of Lipid Research 49:3, pages 635-643.
Crossref
Crossref
Peter Collins. (2008) HDL-C in post-menopausal women: An important therapeutic target. International Journal of Cardiology 124:3, pages 275-282.
Crossref
Crossref
M. Sandri, S. Gielen & G. Schuler. (2008) Prävention der koronaren HerzerkrankungPrevention of coronary artery disease. Der Internist 49:2, pages 154-161.
Crossref
Crossref
Maureen E. Mays & Carlos A. Dujovne. (2008) Pleiotropic effects: Should statins be considered an essential component in the treatment of dyslipidemia?. Current Atherosclerosis Reports 10:1, pages 45-52.
Crossref
Crossref
Lin Ye, Ronald Eitenmiller & W Landen. 2007. Vitamin Analysis for the Health and Food Sciences, Second Edition. Vitamin Analysis for the Health and Food Sciences, Second Edition
361
400
.
John M. Morgan, Margarita de la Llera-Moya & David M. Capuzzi. (2007) Effects of niacin and Niaspan on HDL lipoprotein cellular SR-BI?mediated cholesterol efflux. Journal of Clinical Lipidology 1:6, pages 614-619.
Crossref
Crossref
Michael H. Davidson & Peter P. Toth. (2007) High-Density Lipoprotein Metabolism: Potential Therapeutic Targets. The American Journal of Cardiology 100:11, pages S32-S40.
Crossref
Crossref
A. S. Wierzbicki. (2007) Intervening on HDL-C: Is it possible? Does it work?*. International Journal of Clinical Practice 61:11, pages 1782-1786.
Crossref
Crossref
A. Vogt, U. Kassner, U. Hostalek & E. Steinhagen-Thiessen. (2007) Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan®). International Journal of Clinical Practice 61:11, pages 1914-1921.
Crossref
Crossref
. (2007) Gu?a de Pr?ctica Cl?nica para el diagn?stico y tratamiento del s?ndrome coronario agudo sin elevaci?n del segmento ST. Revista Espa?ola de Cardiolog?a 60:10, pages 1070.e1-1070.e80.
Crossref
Crossref
Ping Wang, Marleen M. J. van Greevenbroek, Freek G. Bouwman, Martijn C. G. J. Brouwers, Carla J. H. van der Kallen, Egbert Smit, Jaap Keijer & Edwin C. M. Mariman. (2007) The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflügers Archiv - European Journal of Physiology 454:6.
Crossref
Crossref
F. Cohen Aubart, B. Hansel, J.-S. Hulot, P. Lechat & E. Bruckert. (2007) Avanc?es r?centes et?perspectives dans?le?traitement des?dyslipid?mies ath?rog?nes. La Revue de M?decine Interne 28:8, pages 537-544.
Crossref
Crossref
Eric Van Ganse, Laurent Laforest, Thomas Burke, Hemant Phatak & Thierry Souchet. (2007) Mixed Dyslipidemia Among Patients Using Lipid-Lowering Therapy in French General Practice: An Observational Study. Clinical Therapeutics 29:8, pages 1671-1681.
Crossref
Crossref
William C. Cromwell, Harold E. Bays & Peter P. Toth. 2007. Markers in Cardiology. Markers in Cardiology
217
250
.
. 2007. Comprehensive Management of High Risk Cardiovascular Patients. Comprehensive Management of High Risk Cardiovascular Patients
295
339
.
Anthony S. Wierzbicki. (2007) Raising HDL-C: back to the future?. International Journal of Clinical Practice 61:7, pages 1069-1071.
Crossref
Crossref
Jieli Chen, Xu Cui, Alex Zacharek, Hao Jiang, Cynthia Roberts, Chunling Zhang, Mei Lu, Alissa Kapke, Carolyn S. Feldkamp & Michael Chopp. (2007) Niaspan increases angiogenesis and improves functional recovery after stroke. Annals of Neurology 62:1, pages 49-58.
Crossref
Crossref
Donna Polk & P.K. Shah. (2007) Cholesterol ester transfer protein (CETP) and atherosclerosis. Drug Discovery Today: Therapeutic Strategies 4:2, pages 137-145.
Crossref
Crossref
Anthony S. Wierzbicki. (2007) Lipid-Altering Therapies and the Progression of Atherosclerotic Disease. CardioVascular and Interventional Radiology.
Crossref
Crossref
Anthony S Wierzbicki. (2016) Voodoo medicine — cardiovascular trials jinxed in New Orleans. The British Journal of Diabetes & Vascular Disease 7:3, pages 142-144.
Crossref
Crossref
Willem Soudijn, Ineke van Wijngaarden & Adriaan P. IJzerman. (2007) Nicotinic acid receptor subtypes and their ligands. Medicinal Research Reviews 27:3, pages 417-433.
Crossref
Crossref
E. Bruckert, M. Baccara-Dinet & E. Eschwege. (2007) Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabetic Medicine 24:4, pages 388-391.
Crossref
Crossref
Gerd Schmitz, Anna Schmitz-Mądry & Peter Ugocsai. (2007) Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Current Opinion in Lipidology 18:2, pages 164-173.
Crossref
Crossref
Anthony S. Wierzbicki. (2007) Lipid-Altering Therapies and the Progression of Atherosclerotic Disease. CardioVascular and Interventional Radiology 30:2, pages 155-160.
Crossref
Crossref
Duncan Emerton. (2007) Dyslipidaemia: Focus shifts from LDL-C to HDL-C. Journal of Commercial Biotechnology 13:2, pages 120-124.
Crossref
Crossref
Prediman K. Shah. (2008) Emerging HDL-based therapies for atherothrombotic vascular disease. Current Treatment Options in Cardiovascular Medicine 9:1, pages 60-70.
Crossref
Crossref
Chaitanya A. Sarawate, Mark J. Cziraky, Eric J. Stanek, Vincent J. Willey, John C. Corbelli & Scott L. Charland. (2007) Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?. Clinical Therapeutics 29:1, pages 196-209.
Crossref
Crossref
Dibyendu De & Ish Khanna. 2007. Annual Reports in Medicinal Chemistry Volume 42. Annual Reports in Medicinal Chemistry Volume 42
177
191
.
Peter P. Toth. (2007) Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. Current Atherosclerosis Reports 9:1, pages 81-88.
Crossref
Crossref
Peter P. Toth. 2007. Therapeutic Lipidology. Therapeutic Lipidology
159
199
.
Natalia Volkova & Prakash Deedwania. 2006. Metabolic Syndrome and Cardiovascular Disease. Metabolic Syndrome and Cardiovascular Disease
191
217
.
Michael H. Davidson, James M. McKenney, Charles L. Shear & James H. Revkin. (2006) Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels. Journal of the American College of Cardiology 48:9, pages 1774-1781.
Crossref
Crossref
Peter P Toth & Antonio M GottoJrJr. 2006. Comprehensive Management of High Risk Cardiovascular Patients. Comprehensive Management of High Risk Cardiovascular Patients
295
340
.
Anthony S. Wierzbicki. (2006) Low HDL-cholesterol: common and under-treated, but which drug to use?. International Journal of Clinical Practice 60:10, pages 1149-1153.
Crossref
Crossref
M. John Chapman. (2006) How does nicotinic acid modify the lipid profile?. European Heart Journal Supplements 8:suppl_F, pages F54-F59.
Crossref
Crossref
Philip Barter. (2006) Options for therapeutic intervention: how effective are the different agents?. European Heart Journal Supplements 8:suppl_F, pages F47-F53.
Crossref
Crossref
Anthony S. Wierzbicki. (2006) Diabetic dyslipidaemia: the triad. European Heart Journal Supplements 8:suppl_F, pages F30-F33.
Crossref
Crossref
Heinz Drexel. (2006) Reducing risk by raising HDL-cholesterol: the evidence. European Heart Journal Supplements 8:suppl_F, pages F23-F29.
Crossref
Crossref
Eric Bruckert. (2006) Epidemiology of low HDL-cholesterol: results of studies and surveys. European Heart Journal Supplements 8:suppl_F, pages F17-F22.
Crossref
Crossref
Terje R. Pedersen. (2006) The gap between theory and practice: what do the trials tell us?. European Heart Journal Supplements 8:suppl_F, pages F10-F16.
Crossref
Crossref
Cesare R. Sirtori. (2006) HDL and the progression of atherosclerosis: new insights. European Heart Journal Supplements 8:suppl_F, pages F4-F9.
Crossref
Crossref
Terje R Pedersen, Gerd Assmann, Jean-Pierre Bassand, M John Chapman, Raimund Erbel & Cesare Sirtori. (2016) Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. Diabetes and Vascular Disease Research 3:2_suppl, pages S1-S12.
Crossref
Crossref
A. Kontush. (2006) Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis. Pharmacological Reviews 58:3, pages 342-374.
Crossref
Crossref
M. John Chapman. (2006) Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacology & Therapeutics 111:3, pages 893-908.
Crossref
Crossref
Lars A Carlson. (2006) Nicotinic acid and other therapies for raising high-density lipoprotein. Current Opinion in Cardiology 21:4, pages 336-344.
Crossref
Crossref
Michel R. Langlois & Victor H. Blaton. (2006) Historical milestones in measurement of HDL-cholesterol: Impact on clinical and laboratory practice. Clinica Chimica Acta 369:2, pages 168-178.
Crossref
Crossref
Rodrigo O. Moreira, Raul D. Santos, Lilton Martinez, Fabiana C. Saldanha, Jara Lucia A.C. Pimenta, Josefina Feijoo, Natalie Jahnke, Otávio C. Mangile & Rosane Kupfer. (2006) Perfil lipídico de pacientes com alto risco para eventos cardiovasculares na prática clínica diária. Arquivos Brasileiros de Endocrinologia & Metabologia 50:3, pages 481-489.
Crossref
Crossref
Cesare R. Sirtori & Remo Fumagalli. (2006) LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. Atherosclerosis 186:1, pages 1-11.
Crossref
Crossref
Anatol Kontush & M John Chapman. (2006) Antiatherogenic small, dense HDL—guardian angel of the arterial wall?. Nature Clinical Practice Cardiovascular Medicine 3:3, pages 144-153.
Crossref
Crossref
Carol E. Koro, Steven J. Bowlin, Timothy E. Stump, Dennis L. Sprecher & William M. Tierney. (2006) The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. American Heart Journal 151:3, pages 755.e1-755.e6.
Crossref
Crossref
Gerd Schmitz & Thomas Langmann. (2006) Pharmacogenomics of cholesterol-lowering therapy. Vascular Pharmacology 44:2, pages 75-89.
Crossref
Crossref
Philip J. Barter & John J.P. Kastelein. (2006) Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease. Journal of the American College of Cardiology 47:3, pages 492-499.
Crossref
Crossref
Yu-Hua Sun, Yue-Jin Yang, Wei-Dong Pei, Yong-Jian Wu & Run-Lin Gao. (2006) Patients With Low High-Density Lipoprotein-Cholesterol or Smoking are More Likely to Develop Myocardial Infarction Among Subjects With a Visible Lesion or Stenosis in Coronary Artery. Circulation Journal 70:12, pages 1602-1605.
Crossref
Crossref
A. Steinmetz. (2006) Chronische Therapie des metabolischen Syndroms bei herzoperierten DiabetikernLong-standing therapy of the metabolic syndrome in diabetics after coronary artery bypass surgery. Clinical Research in Cardiology 95:S1, pages i110-i116.
Crossref
Crossref
Michael Schachter. (2006) Strategies for Modifying High-Density Lipoprotein Cholesterol: A Role for Nicotinic Acid. Cardiovascular Drugs and Therapy 19:6, pages 415-422.
Crossref
Crossref
Ian S. Young. (2016) Lipids for Psychiatrists - an overview. Journal of Psychopharmacology 19:6_suppl, pages 66-75.
Crossref
Crossref
E. N. Liberopoulos, D. P. Mikhailidis & M. S. Elisaf. (2005) Diagnosis and management of the metabolic syndrome in obesity. Obesity Reviews 6:4, pages 283-296.
Crossref
Crossref
Anatol Kontush, Eliana Cotta de Faria, Sandrine Chantepie & M. John Chapman. (2005) A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 182:2, pages 277-285.
Crossref
Crossref
P. Mathes & J. Thiery. (2005) Die Rolle des Lipidstoffwechsels in der Prävention der koronaren HerzerkrankungThe role of lipid metabolism in the prevention of coronary heart disease. Zeitschrift für Kardiologie 94:S3, pages iii43-iii55.
Crossref
Crossref
L. A. CARLSON. (2005) Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. Journal of Internal Medicine 258:2, pages 94-114.
Crossref
Crossref
M John Chapman. (2005) Does raising high-density lipoprotein cholesterol level benefit patients with coronary artery disease?. Nature Clinical Practice Cardiovascular Medicine 2:8, pages 394-395.
Crossref
Crossref
David Brückner, Frank-Thorsten Hafner, Volkhart Li, Carsten Schmeck, Joachim Telser, Alexandros Vakalopoulos & Gabriele Wirtz. (2005) Dibenzodioxocinones—A new class of CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 15:15, pages 3611-3614.
Crossref
Crossref
Christos S KatsourasLoukas D TsironisMoses ElisafJohn A GoodevenosLampros K MichalisAlexandros D Tselepis. (2005) Lipoprotein(a) as a cardiovascular risk factor. Future Cardiology 1:4, pages 509-517.
Crossref
Crossref
Vanessa DeClercq, Behzad Yeganeh, Ghollam-Reza Moshtaghi-Kashanian, Haidar Khademi, Babak Bahadori & Mohammed H Moghadasian. (2005) Paradoxical Effects of Fenofibrate and Nicotinic Acid in Apo E-Deficient Mice. Journal of Cardiovascular Pharmacology 46:1, pages 18-24.
Crossref
Crossref
John Chapman. (2005) Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. European Heart Journal Supplements 7:suppl_F, pages F56-F62.
Crossref
Crossref
B. Greg Brown. (2005) Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. European Heart Journal Supplements 7:suppl_F, pages F34-F40.
Crossref
Crossref
John J.P. Kastelein. (2005) The realities of dyslipidaemia: what do the studies tell us?. European Heart Journal Supplements 7:suppl_F, pages F27-F33.
Crossref
Crossref
Eric Bruckert, Raymond Pamphile, Fran McCoy & Philippe André. (2005) Defining the prevalence of low HDL-C in a European cohort of dyslipidaemic patients. European Heart Journal Supplements 7:suppl_F, pages F23-F26.
Crossref
Crossref
Gerd Schmitz & Thomas Langmann. (2005) Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1735:1, pages 1-19.
Crossref
Crossref
Philip Barter. (2016) Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. The British Journal of Diabetes & Vascular Disease 5:2_suppl, pages S1-S15.
Crossref
Crossref
Justin Ms Lee & Robin P Choudhury. (2016) ARBITER 2: targeting HDL to retard atherosclerosis progression. The British Journal of Diabetes & Vascular Disease 5:2, pages 78-80.
Crossref
Crossref
Philip Barter. (2016) The realities of dyslipidaemia in metabolic syndrome and diabetes. The British Journal of Diabetes & Vascular Disease 5:1_suppl, pages S7-S11.
Crossref
Crossref
Displaying 200 of 203 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list